Traws Pharma (TRAW) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on unmet medical needs in respiratory viral diseases and cancer.

• Pipeline includes an oral CAP-dependent inhibitor for influenza, an oral antiviral for SARS-CoV-2, and a multi-kinase CDK4-plus inhibitor for refractory endometrial cancer and other cancers.

• Recently acquired Trawsfynydd Therapeutics, making it a wholly owned subsidiary.

Financial performance and metrics

• Financial statements for the year ended December 31, 2023, audited by Ernst & Young LLP, include a going concern warning.

• Trawsfynydd Therapeutics' financials also include a going concern warning from EisnerAmper LLP.

• As of June 27, 2024, 25,306,509 shares of common stock were outstanding, with 12,472.7687 shares of Series C Preferred Stock potentially convertible into 124,727,687 shares of common stock.

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by selling stockholders.

• All proceeds from share sales will go to the selling stockholders, not the company.